CureVac (CVAC) Projected to Post Earnings on Thursday

Key Points

• CureVac (CVAC) is set to release its Q2 2025 earnings results on August 21st, with analysts projecting a loss of ($0.15) per share and revenue of $4.27 million.
• In its last earnings announcement, the company reported a loss of ($0.24) per share and significantly missed revenue expectations, raising concerns about its financial performance.
• Following recent adjustments, the consensus rating for CureVac's stock is "Hold" with an average price target of $6.83 after several analysts revised their ratings and targets downward.

CureVac (NASDAQ:CVAC - Get Free Report) is expected to be issuing its Q2 2025 quarterly earnings data before the market opens on Thursday, August 21st. Analysts expect the company to announce earnings of ($0.15) per share and revenue of $4.27 million for the quarter.

CureVac (NASDAQ:CVAC - Get Free Report) last released its earnings results on Thursday, May 22nd. The company reported ($0.24) earnings per share for the quarter, missing analysts' consensus estimates of ($0.16) by ($0.08). The firm had revenue of $0.94 million for the quarter, compared to analysts' expectations of $4.27 million. CureVac had a return on equity of 30.89% and a net margin of 35.44%. On average, analysts expect CureVac to post $1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

CureVac Stock Down 0.6%

Shares of NASDAQ:CVAC traded down $0.04 during trading on Monday, hitting $5.45. 78,609 shares of the company were exchanged, compared to its average volume of 960,261. The stock has a market capitalization of $1.22 billion, a P/E ratio of 5.93 and a beta of 2.53. The company has a debt-to-equity ratio of 0.05, a current ratio of 7.65 and a quick ratio of 7.64. CureVac has a 12-month low of $2.37 and a 12-month high of $5.72. The firm's 50 day moving average price is $5.37 and its 200-day moving average price is $4.09.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on CVAC shares. JMP Securities restated a "market outperform" rating and set a $10.00 target price on shares of CureVac in a research report on Wednesday, May 28th. Jefferies Financial Group reissued a "hold" rating and issued a $5.00 price objective (down from $7.00) on shares of CureVac in a research note on Friday, June 13th. Citigroup cut shares of CureVac to a "market perform" rating in a research note on Thursday, June 12th. UBS Group cut shares of CureVac from a "strong-buy" rating to a "neutral" rating and dropped their price objective for the company from $12.00 to $5.50 in a research note on Thursday, June 26th. Finally, Citizens Jmp cut shares of CureVac from a "strong-buy" rating to a "hold" rating in a research note on Thursday, June 12th. Four investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company's stock. According to data from MarketBeat.com, CureVac currently has an average rating of "Hold" and a consensus price target of $6.83.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Headlands Technologies LLC acquired a new position in shares of CureVac during the 2nd quarter valued at about $35,000. Water Island Capital LLC acquired a new position in shares of CureVac during the 2nd quarter valued at about $5,197,000. BNP Paribas Financial Markets raised its position in shares of CureVac by 12.9% in the 2nd quarter. BNP Paribas Financial Markets now owns 253,462 shares of the company's stock worth $1,376,000 after buying an additional 28,939 shares during the period. Bank of America Corp DE raised its position in shares of CureVac by 1,056.0% in the 2nd quarter. Bank of America Corp DE now owns 95,470 shares of the company's stock worth $518,000 after buying an additional 87,211 shares during the period. Finally, AQR Arbitrage LLC acquired a new stake in CureVac during the 2nd quarter worth approximately $240,000. 17.26% of the stock is currently owned by hedge funds and other institutional investors.

CureVac Company Profile

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.